Please wait, loading...
Is the FSA's policy that any CBD "New to Market" products will be treated differently than those "Already on the Market" justified despite there being no difference in their potential risks? Perhaps the more telling question is whether the policy will be sustained in the face of an inevitable legal challenge?
In May we published an analysis of the Judgement of Advocate General Tanchev in respect of the Kanavape case, “Can the movement of CBD within the European Member States be prohibited it if is derived from prohibited elements of the plant?”
The recent news that Mike Harlington, the now ex-Chairman of the CTA, has been ousted by the organisation’s board (now led by Tom Whettem) was reported by The Canna Consultants here. The news led us to take a delve into TrustCanna... and what did we find?
It was with interest that on the evening of 13th June 2020 we discovered (from the Business Cann website) that, what we at The Canna Consultants had thought was on the cards for many months, had actually come to pass. The headline read ““Disagreement” sees Europe’s largest trade association lose its Chairman”.
The race for earliest submission of a Novel Food Dossier is a false one. This is especially the case when submissions made thus far, so we understand, lack the appropriate scientific data in respect of end products for which Authorisation is being contended and, in some cases, lack any scientific data in respect of the subject of the application at all.
On 14th May 2020 the Advocate General (Tanchev) of the Court of Justice of the European Union (CJEU) delivered their Opinion on the above question. The result is both a “Yes” and a “No”: National restrictions by Member States are possible, but such restrictions as are sought to be enforced must be (a) justified and (b) no more than necessary in order to achieve the justified aim.
Another snippet from the Global Cannabis Town Hall. Discussing collegiate Novel Food Applications and the potential issues with proprietary data. Answering questions on the future of the CBD Industry and the impact of Novel Foods post Covid-19. Watch the video here with Steve Oliver answering the question during the First Global Cannabinoid Webinar.
During the Global Cannabis Town Hall we were asked whether we thought other EU states would follow the FSA's lead and grant their own transition period 'passes' for Novel Food applicants. Watch the video here with Steve Oliver answering the question during the First Global Cannabinoid Webinar.
Novel Foods applications, submissions and the challenge with toxicology tests. Watch the video here with Steve Oliver answering industry questions during the First Global Cannabinoid Webinar.
Steve Oliver and Matt Lawson, Co-Founders of The Canna Consultants, are representing the UK in RASB Media's one hour 'UK Market Special Segment' broadcast.